Cerebrospinal fluid proteomics in patients with Alzheimer’s disease reveals five molecular subtypes with distinct genetic risk profiles
[ad_1] We analyzed CSF samples from 609 individuals that were selected from the Alzheimer Center Amsterdam related studies15,16,17,18 (for clinical details, see Methods and Supplementary Table 1). Of this sample, 419 individuals had AD as defined by an abnormal amyloid biomarker and included all clinical stages (that is, 107 with normal cognition, 103 with mild … Read more